| PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology 37 (6), 490-503, 2019 | 325 | 2019 |
| Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer V Conteduca, A Jayaram, N Romero-Laorden, D Wetterskog, S Salvi, ... European urology 75 (3), 368-373, 2019 | 78 | 2019 |
| Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting J Puente, E Grande, A Medina, P Maroto, N Lainez, JA Arranz Therapeutic advances in medical oncology 9 (5), 307-318, 2017 | 62 | 2017 |
| Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study J Ruiz-Bañobre, A Molina-Díaz, O Fernández-Calvo, N Fernández-Núñez, ... ESMO open 6 (2), 100090, 2021 | 36 | 2021 |
| Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer V Conteduca, E Castro, D Wetterskog, E Scarpi, A Jayaram, ... European Journal of Cancer 116, 158-168, 2019 | 34 | 2019 |
| Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective … X Garcia del Muro, BP Valderrama, A Medina, MA Cuellar, O Etxaniz, ... Journal of Clinical Oncology 39 (15_suppl), 4505-4505, 2021 | 32 | 2021 |
| HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two … DJ Khalaf, IM Aragón, M Annala, R Lozano, S Taavitsainen, D Lorente, ... Annals of Oncology 31 (9), 1186-1197, 2020 | 27 | 2020 |
| A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN) J Bellmunt, JM Kerst, F Vazquez, R Morales-Barrera, E Grande, A Medina, ... Annals of Oncology 28 (7), 1517-1522, 2017 | 24 | 2017 |
| PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC) EC Marcos, NR Laorden, JMP Rodriguez, A del Pozo, MI Sáez, ... Annals of Oncology 28, v619, 2017 | 15 | 2017 |
| Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC) E Castro, RL Mejorada, M Saez, I Aragón, NR Laorden, ... Annals of Oncology 30, v343-v344, 2019 | 12 | 2019 |
| Choriocarcinoma syndrome. A Medina, M Ramos, M Amenedo, L París Archivos Españoles de Urología 67 (8), 711-714, 2014 | 12 | 2014 |
| Association between second progression-free survival (PFS2) and overall survival in metastatic castration-resistant prostate cancer D Lorente, E Castro, R Lozano, J Puente, N Romero-Laorden, ... European urology 77 (6), 763-766, 2020 | 10 | 2020 |
| Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study. MA Cuellar, A Medina, R Girones, BP Valderrama, A Font, MJ Juan-fita, ... Journal of Clinical Oncology 38 (15_suppl), TPS5097-TPS5097, 2020 | 6 | 2020 |
| Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer U Anido-Herranz, N Fernández-Núñez, J Afonso-Afonso, ... Clinical and Translational Oncology 21, 249-258, 2019 | 6 | 2019 |
| Metastatic bladder cancer: second-line treatment and recommendations of the genitourinary tumor division of the Galician Oncologic Society (SOG-GU) J García, L Santomé, U Anido, O Fernández-Calvo, J Afonso-Afonso, ... Current oncology reports 18, 1-12, 2016 | 6 | 2016 |
| Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. R Lozano, E Castro, JM Piulats, A Medina, JCV Guzman, ... Journal of Clinical Oncology 37 (7_suppl), 264-264, 2019 | 4 | 2019 |
| 590P PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination (HR) genes on the response to radium-223 for metastatic castration … E Castro, RL Mejorada, A Medina, U Giorgi, NR Laorden, V Conteduca, ... Annals of Oncology 32, S638-S639, 2021 | 3 | 2021 |
| Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with … IM Aragon, Y Cendón, D Lorente, RL Mejorada, NR Laorden, ... Annals of Oncology 30, v346, 2019 | 3 | 2019 |
| Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: the proradium study N Romero-Laorden, D Lorente, G de Velasco, R Lozano, B Herrera, ... European Urology Oncology 7 (3), 447-455, 2024 | 2 | 2024 |
| Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck A Gogate, B Bennett, Z Poonja, G Stewart, A Medina Colmenero, P Szturz, ... Cancers 15 (14), 3552, 2023 | 2 | 2023 |
